HSP90AA1 and plasma cell myeloma: In particular, the sensitivity of aneuploid cancer cells to Hsp90 inhibition seems to reflect the increased proteotoxic stress associated to the accumulation of misfolded proteins, as supported by the evidence that Hsp90 inhibition potentiates the effects of proteasome inhibitors in multiple myeloma [62,63].